How Platelet-Rich Plasma (PRP) Transformed My Asthma Management: A Personal Journey and Emerging Therapeutic Frontier
A Story of Innovation Through Experience
Born nearly three months premature and weighing less than two pounds, my life began with grim predictions of blindness, deafness, and severe impairments. While I defied these odds and led a relatively normal life, I faced a significant challenge: asthma. Every year for the first 16 years of my life, I endured pneumonia, repeated hospitalizations, and a daily reliance on nebulizers and albuterol rescue inhalers. Relief came only partially when I participated in a clinical trial for Pulmicort and Foradil at age 16, and later, daily oral Prednisone stabilized my symptoms.
However, long-term use of steroids was not without their side effects and as I transitioned into adulthood, I sought to take control of my health beyond traditional medical prescriptions and explore potential solutions through regenerative medicine. This journey led me to a groundbreaking discovery in asthma management, culminating in the creation of nebulized PRP therapy — a solution that has profoundly changed my life!
The Path to Discovery: From Nebulized Lidocaine to PRP
Inspired by research on nebulized lidocaine, I experimented with self-administering a diluted solution to alleviate asthma symptoms. While this protocol allowed me to reduce my reliance on oral steroids and inhalers, I sought a more permanent approach. My work with regenerative medicine introduced me to the potential of PRP in respiratory therapy. However, intravenous administration seemed insufficient for targeted pulmonary issues. That’s when I envisioned nebulized PRP as a more direct and effective application.
Using the Juventix 12ML2 PRP kit, I prepared concentrated PRP buffered with sterile saline. Administering treatments twice daily for three weeks, I experienced remarkable results: I discontinued all prescription medications, and I haven’t touched a rescue inhaler in over six years since!
Scientific Evidence Supporting PRP in Respiratory Disorders
PRP’s therapeutic potential in respiratory health is supported by a growing body of research:
- Tissue Repair and Inflammation Modulation: PRP contains growth factors such as VEGF, PDGF-BB, and TGF-beta that promote revascularization, reduce pulmonary vascular inflammation, and enhance alveolar membrane integrity. These mechanisms facilitate better oxygen exchange and reduce the cardiopulmonary workload.
- The Role of Platelets in Lung Function: Studies have shown that the lungs play a significant role in platelet production and function, further supporting PRP’s suitability for pulmonary therapies (Looney et al., 2017).
- Exploring The Clinical Evidence:
- A study published in Cureus examined the efficacy of PRP therapy in patients with chronic respiratory diseases. The findings suggested that PRP treatment contributed to lung tissue regeneration, thereby decelerating disease progression and enhancing patients’ quality of life. Cureus
-
- COPD Treatment: An observational cohort study involving 419 COPD patients assessed the impact of autologous PRP therapy on lung function. Results indicated improvements in forced expiratory volume (FEV1) percentages and enhanced quality of life post-treatment. Athenaeum Publishing
- Bronchopleural Fistula Management: Research published in Archivos de Bronconeumología evaluated the safety and efficacy of PRP in treating bronchopleural fistulas. The study concluded that PRP application was a safe and effective adjunct therapy, promoting healing in patients with this challenging condition. Archivos de Bronconeumología
Juventix Regenerative Medical: Advancing PRP Therapy
Juventix Regenerative Medical provides high-quality, scientifically validated PRP kits designed for regenerative therapies. Their user-friendly kits allow clinicians to efficiently prepare PRP for innovative treatments quickly and effectively at an industry-low cost of goods amongst FDA-cleared devices. By leveraging Juventix PRP, practitioners can offer patients a non-invasive, cost-effective, and scientifically backed therapy. While PRP is not yet FDA-cleared specifically for respiratory ailments, emerging clinical literature, and case studies such as my own provide hope for further development of PRP as a safe, effective, autologous solution to a wide range of respiratory disorders.
Limited-Time Offer: Experience Juventix PRP
To help practitioners explore PRP’s potential, Juventix offers a sample PRP kit at a special price of $20. Request a sample by emailing hello@juventix.com with the subject line “SAMPLE” or by visiting the Juventix Sample Page.
Explore the Future of Regenerative Medicine
Discover the possibilities with Juventix PRP by scheduling a free introductory webinar, visiting www.juventix.com, or calling (866) 693-4777.
Restore, Revive, Regenerate™ — Juventix Regenerative Medical.
About the Author: Lance Liberti is a nationally recognized healthcare consultant and new patient marketing professional with more than two decades of practical experience in the field. His experience spans multiple areas of practice including non-surgical spinal decompression, medically supervised weight loss, aesthetic medicine, and non-operative extremity pain management. The president and CEO of Integrative Practice Solutions and Juventix Regenerative Medical Mr. Liberti specializes in assisting health and wellness professionals to integrate boutique medical services into their practices to offer non-surgical solutions to those suffering from various degenerative musculoskeletal conditions. To learn more about Mr. Liberti’s extensive experience and see examples of his work products view his LinkedIn profile here: https://www.linkedin.com/in/lanceliberti
References
- Mohamed, R., et al. (2014). Nebulized lidocaine inhalation in the treatment of patients with acute asthma. BMC Pulmonary Medicine, 14(94). Link
- Louie, S., et al. (2004). Treatment of asthma with nebulized lidocaine: A randomized, placebo-controlled study. Chest, 125(5), 1591-1595. Link
- Knight, A., & Kacker, S. (2023). Platelet-Rich Plasma Treatment for Chronic Respiratory Disease. Cureus, 15(1), e33265. Link
- Lefrançais, E., et al. (2017). The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature, 544(7648), 105-109. Link
- Roussey Y., et al. (2007). Platelet-Derived Growth Factors in Pulmonary Therapy. Clinical Oral Implants Research.
Legal Disclaimer
The information contained in this article is provided for informational purposes only and should not be construed as medical or legal advice on any subject matter. You should not act or refrain from acting on the basis of any content included in this article without seeking medical, legal, or other professional advice. The contents of this article contain general information and may not reflect current legal developments or address your situation. We disclaim all liability for actions you take or fail to take based on any content of this article.
